TY - JOUR AU - Feng, Liang AU - Yao, Hang-Ping AU - Sharma, Sharad AU - Zhou, Yong-Qing AU - Zhou, Jianwei AU - Zhang, Ruiwen AU - Wang, Ming-Hai PY - 2016 DA - 2016/04/22 TI - Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer JO - Journal of Experimental & Clinical Cancer Research SP - 70 VL - 35 IS - 1 AB - Aberrant expression of the RON receptor tyrosine kinase, a member of the MET proto-oncogene family, in breast cancer and non-small cell lung cancer (NSCLC) has therapeutic implication. Here we evaluated the efficacy of a novel anti-RON antibody-drug maytansinoid conjugate Zt/g4-DM1 for treatment of breast and NSCLC xenograft tumors in mouse models and explored a treatment strategy by combination of Zt/g4-DM1 with chemotherapeutics to achieve the maximal therapeutic activity. SN - 1756-9966 UR - https://doi.org/10.1186/s13046-016-0347-6 DO - 10.1186/s13046-016-0347-6 ID - Feng2016 ER -